Evidence map›Paper›PMID 35908075›Full record

ArticleNature communications2022

Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy.

Mary Prahl, Yarden Golan, Arianna G Cassidy, Yusuke Matsui, Lin Li, Bonny Alvarenga, Hao Chen, Unurzul Jigmeddagva, Christine Y Lin, Veronica J Gonzalez and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. COVID-19 Vaccine mRNA Biodistribution: Maternal and Fetal Exposure Risks.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Mary PrahlDepartment of Pediatrics, University of California, San Francisco, CA, USA. mary.prahl@ucsf.edu.ORCID 0000-0003-0091-2731
Yarden GolanDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.
Arianna G CassidyDivision of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Yusuke MatsuiGladstone Center for HIV Cure Research, Gladstone Institute, San Francisco, CA, USA.
Lin LiDivision of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Bonny AlvarengaDepartment of Neurology, University of California, San Francisco, CA, USA.ORCID 0000-0001-7922-9454
Hao ChenCenter for Reproductive Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Unurzul JigmeddagvaCenter for Reproductive Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Christine Y LinDivision of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Veronica J GonzalezDivision of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Megan A ChidboyDivision of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Lakshmi WarrierDepartment of Medicine, University of California, San Francisco, CA, USA.
Sirirak BuarpungDivision of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Amy P MurthaCenter for Reproductive Sciences, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.
Valerie J FlahermanDepartment of Pediatrics, University of California, San Francisco, CA, USA.
Warner C GreeneGladstone Center for HIV Cure Research, Gladstone Institute, San Francisco, CA, USA.
Alan H B WuDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Kara L LynchDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0003-1367-0401
Jayant RajanDepartment of Medicine, University of California, San Francisco, CA, USA.
Stephanie L GawDivision of Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA. Stephanie.Gaw@ucsf.edu.ORCID 0000-0003-0891-6964

Funding

The Immunologic Impact of In Utero Malaria Exposure and Prenatal ChemopreventionK23AI127886 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRAHL, MARY · 2017 to 2021
$1.0M
Placental malaria: The role of inflammation at the maternal-fetal interfaceK08AI141728 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GAW, STEPHANIE LINA · 2019 to 2023
$950k
NIAID NIH HHS K08 AI141728NIAID NIH HHS K23 AI127886
6 · The paper itself

Abstract

Studies are needed to evaluate the safety and effectiveness of mRNA SARS-CoV-2 vaccination during pregnancy, and the levels of protection provided to their newborns through placental transfer of antibodies. Here, we evaluate the transplacental transfer of mRNA vaccine products and functional anti-SARS-CoV-2 antibodies during pregnancy and early infancy in a cohort of 20 individuals vaccinated during late pregnancy. We find no evidence of mRNA vaccine products in maternal blood, placenta tissue, or cord blood at delivery. However, we find time-dependent efficient transfer of IgG and neutralizing antibodies to the neonate that persists during early infancy. Additionally, using phage immunoprecipitation sequencing, we find a vaccine-specific signature of SARS-CoV-2 Spike protein epitope binding that is transplacentally transferred during pregnancy. Timing of vaccination during pregnancy is critical to ensure transplacental transfer of protective antibodies during early infancy.

Indexed as

COVID-19Pregnancy Complications, InfectiousAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesFemaleHumansImmunoglobulin GInfant, NewbornmRNA VaccinesPlacentaPregnancyRNA, MessengerSARS-CoV-2Spike Glycoprotein, CoronavirusVaccines, SyntheticAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GmRNA VaccinesRNA, MessengerSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Synthetic

Identifiers

PMID35908075
PMCPMC9338928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.